LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Strona główna・Stock List・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Closed

SectorHealthcare

1.4 -0.71

Buy Sell

Overview

Share price change

24h

Current

Min

1.38

Max

1.44

Key metrics
By Trading Economics
Income	-16M -13M
Sales	-15M 14M
EPS	-0.04
Profit margin	-90.037
Employees	103
EBITDA	-16M -10M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+179.58% upside

Market Stats
By TradingEconomics
Market Cap	494M
Previous open	2.11
Previous close	1.4

News Sentiment

By Acuity

50%

184 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

0.6863 / 0.72 Support & Resistance

Lexicon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 gru 2025, 21:08 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Buys AI-Device Maker Limitless

5 gru 2025, 19:39 UTC

Major Market Movers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 gru 2025, 19:17 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5 gru 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 gru 2025, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

5 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 gru 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 gru 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 gru 2025, 21:03 UTC

Market Talk

Earnings

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 gru 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 gru 2025, 20:42 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 gru 2025, 20:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 gru 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 gru 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 gru 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5 gru 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 gru 2025, 18:28 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:24 UTC

Acquisitions, Mergers, Takeovers

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 gru 2025, 18:20 UTC

Market Talk

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 gru 2025, 18:11 UTC

Market Talk

The Tale of Two Canadian Employment Indicators -- Market Talk

5 gru 2025, 17:48 UTC

Market Talk

Canadian Youth Unemployment Rate Cools -- Market Talk

5 gru 2025, 17:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

5 gru 2025, 17:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Correction to Imax Market Talk

5 gru 2025, 17:35 UTC

Market Talk

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5 gru 2025, 17:25 UTC

Market Talk

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

179.58% upside

12 Months Forecast

Average 3.97 USD 179.58%

High 6 USD

Low 1.9 USD

Based on 3 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Lexicon Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.6863 / 0.72Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

184 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.